Cholesterol efflux via HDL resecretion occurs when cholesterol transport out of the lysosome is impaired.
Recently, we showed that holo HDL particle uptake and resecretion occur in physiologically relevant cell lines and that HDL uptake is mediated by scavenger receptor class B type I (SR-BI). Furthermore, we established that HDL resecretion is accompanied by [(3)H]cholesterol efflux. This study shows that HDL uptake and resecretion occur even when LDL uptake and cholesterol trafficking are disturbed. First, we used a set of inhibitors that block cholesterol transport out of the lysosome: chloroquine, imipramine, U18666A, and monensin. In all cases, HDL retroendocytosis occurred and HDL resecretion mediated [(3)H]cholesterol efflux, although to a lesser extent. Second, cell lines carrying somatic mutations in intracellular cholesterol transport were used: CHO 2-2 and CHO 3-6 cells accumulated LDL-derived lipid in the lysosome but showed all components of HDL retroendocytosis. SR-BI overexpression increased HDL uptake and resecretion and [(3)H]cholesterol efflux in these mutant cells. Finally, we used Niemann-Pick type C (NPC) patient fibroblast cells, which carry a defect in cholesterol transfer out of the lysosome. NPC fibroblast cells accumulate cholesterol in the lysosome as a result of a mutation in the NPC1 gene. Despite disturbed intracellular cholesterol transfer, NPC fibroblast cells exhibited HDL retroendocytosis and [(3)H]cholesterol efflux via HDL resecretion, although to a lesser extent. Thus, [(3)H]cholesterol efflux via HDL resecretion is independent of the cholesterol uptake pathway via the LDL receptor and may be an alternative way to remove excess cholesterol.
Pagler
Tamara A
TA
Center for Physiology and Pathophysiology, Department of Medical Chemistry, Medical University of Vienna, A-1090, Vienna, Austria.
Neuhofer
Angelika
A
Laggner
Hildegard
H
Strobl
Wolfgang
W
Stangl
Herbert
H
D000736:Androstenes / Q000494:pharmacology; D000818:Animals; D001692:Biological Transport; D016466:CHO Cells; D002352:Carrier Proteins / Q000378:metabolism; D002738:Chloroquine / Q000494:pharmacology; D002784:Cholesterol / Q000378:metabolism*; D006224:Cricetinae; D003412:Cricetulus; D004705:Endocytosis; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D007099:Imipramine / Q000494:pharmacology; D047908:Intracellular Signaling Peptides and Proteins; D008075:Lipoproteins, HDL / Q000378:metabolism*; D008247:Lysosomes / Q000378:metabolism*; D008562:Membrane Glycoproteins / Q000378:metabolism; D008985:Monensin / Q000494:pharmacology; D000077296:Niemann-Pick C1 Protein; D051122:Scavenger Receptors, Class B / Q000378:metabolism
D000736:Androstenes; D002352:Carrier Proteins; D047908:Intracellular Signaling Peptides and Proteins; D008075:Lipoproteins, HDL; D008562:Membrane Glycoproteins; C106881:NPC1 protein, human; D000077296:Niemann-Pick C1 Protein; C495124:SCARB1 protein, human; D051122:Scavenger Receptors, Class B; C006261:3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one; D002738:Chloroquine; D008985:Monensin; D002784:Cholesterol; D007099:Imipramine